The biomedical literature has a verification problem — not a discovery problem

Finding papers is no longer the bottleneck. Google Scholar, PubMed, Scopus, and Web of Science together index the vast majority of the biomedical corpus. The real problem is downstream: once you have 200 results for "KRAS G12C resistance mechanisms," how do you know which citations are sound, which have been retracted, and which come from journals with no meaningful peer review?

A 2007 comparison in FASEB Journal found that while PubMed remained optimal for biomedical retrieval, Google Scholar's citation information was of "inconsistent accuracy" and less frequently updated than curated databases (PMID: 17884971). Nearly two decades later, Google Scholar still does not systematically flag retractions, distinguish predatory from legitimate journals, or verify that a cited paper actually supports the claim it is attached to.

This is not a hypothetical risk. A 2019 study in the Journal of the Medical Library Association found that 157 systematic reviews had cited articles from predatory journals discovered through Google Scholar and PubMed, and warned that these databases "do not provide the same level of quality control as other bibliographic databases" (PMID: 30598649).

Retracted biomedical papers keep accumulating citations — and Google Scholar does not stop it

The most dangerous failure mode in biomedical literature is not the missing paper; it is the retracted paper that looks legitimate. A 2022 citation analysis in the Journal of Clinical Epidemiology tracked 153 retracted systematic reviews and found that 60.8% of all citations to those reviews occurred after the retraction notice was published. Only 5% of post-retraction citations acknowledged the retraction (PMID: 35636592).

The problem scales. A 2024 JAMA Network Open study examined retracted microRNA biomarker articles — a field with one of the highest retraction rates in biomedicine — and found 6,327 post-retraction citations across 792 retracted articles. Among those, 78.41% were cited at least once after retraction, and articles that cited retracted papers had 6.57× higher odds of being retracted themselves (PMID: 38512253).

Google Scholar indexes all of these papers. It does not distinguish a retracted study from an active one. Researchers who rely on Google Scholar as their primary discovery tool risk building evidence chains on foundations that have already been formally withdrawn.

The reproducibility crisis compounds the search problem in biomedical research

Even among non-retracted papers, a large fraction of biomedical findings fail to reproduce. A 2022 study in the Journal of the Royal Society Interface used a laboratory automation system to test 74 cancer biology statements automatically extracted from the published literature. Only 22 of 74 — under 30% — showed statistically significant evidence for reproducibility and robustness across two different breast cancer cell lines (PMID: 35382578).

This means that a standard literature search on Google Scholar (or any index) returns a corpus in which a substantial fraction of the underlying experimental claims may not hold. Google Scholar has no mechanism to surface this signal. It ranks by citation count, publication date, and relevance — none of which correlate reliably with experimental reproducibility.

BioSkepsis does not solve reproducibility directly, but it provides the infrastructure that makes evidence quality visible: citation verification, evidence tiering by study design, and flagging of papers with known corrections or retractions. The goal is not to replace experimental validation; it is to stop unreliable evidence from entering the synthesis undetected.

Head-to-head: Google Scholar vs BioSkepsis for biomedical literature

The comparison is not adversarial. Google Scholar and BioSkepsis serve different functions. Google Scholar is a broad-spectrum discovery engine; BioSkepsis is a domain-specific verification and synthesis platform. The question is not which is "better" in the abstract — it is which is appropriate when the stakes involve clinical evidence, drug safety, or research integrity.

What Google Scholar does well — and where biomedical researchers outgrow it

Google Scholar excels at breadth. It covers grey literature, conference proceedings, book chapters, and preprints that curated databases omit. For interdisciplinary discovery — connecting a materials science paper to a drug delivery application — Google Scholar remains unmatched.

But biomedical researchers typically need depth over breadth. A systematic review of SGLT2 inhibitors in heart failure does not benefit from finding a tangentially related engineering thesis. It benefits from knowing that every RCT cited actually exists, that none have been retracted, and that the effect sizes reported in the original papers match the claims in the review.

Google Scholar was designed as a search engine. BioSkepsis was designed as a verification engine. The workflows are complementary, but they are not interchangeable.

How BioSkepsis grounds biomedical claims in PubMed evidence

BioSkepsis operates on a different principle than search. Instead of returning a ranked list of links, it synthesises the literature into claim-level statements, each anchored to one or more verified PMIDs. The verification pipeline checks that each PMID exists in PubMed, that the article metadata matches the claim context, and that the paper has not been retracted or issued a correction.

This design eliminates two of the most common failure modes in literature-informed research: fabricated citations (a known problem with general-purpose LLMs) and stale citations to retracted work (a known problem with unverified search).

Which biomedical researchers should use which tool?

Frequently asked questions